China Concludes First-Ever Securities Class Action With a Slap-on-the-Wrist Order

November 22, 2021 | BY

Jessica Seah

In China's first-ever securities class action, Kangmei Pharmaceuticals has been ordered to pay $385 million as compensation—just enough for 50,000 investors to recoup their losses.

Map of China and a hand Credit: vegefox.com/Adobe Stock

(This article was first published on Law.com International.)

Kangmei Pharmaceuticals, one of China's largest Chinese medicine makers, has been ordered to pay its 50,000 investors $385 million as compensation for their losses on their company's stock. The matter marked closure to the country's first-ever securities class action.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]